Physician profile
Ryan Wakim
NPI 1093033789
$771,682.37
in general payments reported to CMS, 2019-2025
20 companies · $217K in 2025
The $217K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $9,665 · 2021: $25K · 2022: $108K · 2023: $141K · 2024: $256K · 2025: $217K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $277K · Consulting Fee: $144K · Honoraria: $109K · Travel and Lodging: $71K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $276,620.50 |
| Consulting Fee | $144,309.00 |
| Honoraria | $109,155.50 |
| Travel and Lodging | $71,430.78 |
| Food and Beverage | $12,676.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $344,886.07 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $293,587.75 | 2023-2025 | Auvelity |
| Abbvie INC. | $111,452.99 | 2021-2025 | |
| Neuronetics, INC. | $11,350.02 | 2019-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $6,971.34 | 2019-2021 | |
| Teladoc Health, INC. | $2,600.00 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $248.14 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $142.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.79 | 2019-2021 | |
| Indivior INC. | $70.65 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $55.28 | 2020-2021 | |
| Neos Therapeutics, Lp | $38.92 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $38.77 | 2020-2021 | |
| Lundbeck LLC | $37.59 | 2019 | |
| Brainsway USA INC | $34.35 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $30.77 | 2025 | Spravato |
| Mdd US Operations, LLC | $19.98 | 2019 | |
| Biogen, INC. | $15.39 | 2022 | |
| Shire North American Group INC | $14.89 | 2019 | |
| Alfasigma USA, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.